This is very encouraging, but will take a long time to get to any type of usable treatment because these cells are literally made to evade the immune system they run a whole bunch of other risks. Also cell therapies right now are one of the weakest markets in Biotechs due to the level of costs to develop. This is slightly different since it's Allogenic, but the market seems not very invested in cell therapy.
ejstronge|5 months ago
If we're controlling the cells' genomes (which we are), we can add any sort of killswitch (see another comment https://news.ycombinator.com/item?id=45220068 ) that we would like, and this would function better than relying on host immune surveillance. The opposite could be done, making insulin release dependent on the presence of a harmless drug, e.g., insulin release can only happen if a designer steroid molecule is present in the blood.
There are already cell therapies that envisage permanent implantation of modified cells, so I am not sure why a long delay for 'any type of usable treatment' would occur. The structure of this need not be analogous to a stem cell transplant; you could imagine injecting new cells intramuscularly every few months.
The costs to develop this are incurred during development (unlike the autologous therapies that require extensive, expert-level analysis for each new patient). I'm not sure that we can compare the current levels of investment in autologous gene editing to this product.
DarwinsToffees|5 months ago
You are correct that current cell transplant therapies exist, but I don't believe any before have contained these immune escaping edits and I believe all of those treatments are cancer treatments which allow for a different level of risk. Diabetes is a very serious disease but a quality of life treatment does exist and having cells result in a potential cancer in patients would not be acceptable as an outcome.
inglor_cz|5 months ago
So, a subscription... ouch.
I get the medical advantages, but it still sounds as easily abusable economically.